SCHEMBL770488

SCHEMBL770488

CC(C)(C)CCCSCCCC(C)(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14079689 0.97
SCHEMBL769947 0.94
SCHEMBL18844703 0.89 CES1 (0.30)
SCHEMBL6432140 0.88
SCHEMBL25839164 0.87 CYP1A2 (0.32)
SCHEMBL21016180 0.85
SCHEMBL13824137 0.85 TSHR (0.41)
SCHEMBL21481531 0.83
SCHEMBL6505792 0.83
SCHEMBL26081550 0.83

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9988340-B2 Compositions and methods for the treatment of multiple sclerosis CELLIX BIO PRIVATE LIMITED (IN) 2018-06-05 US disclosed
US-9932294-B2 Compositions and methods for the treatment of multiple sclerosis CELLIX BIO PRIVATE LIMITED (IN) 2018-04-03 US disclosed
US-9771355-B2 Compositions and methods for the treatment of epilepsy and neurological disorders CELLIX BIO PRIVATE LIMITED (IN) 2017-09-26 US disclosed
US-9765020-B2 Dichlorophenyl-imino compounds and compositions, and methods for the treatment of mucositis CELLIX BIO PRIVATE LIMITED (IN) 2017-09-19 US disclosed
US-9738631-B2 Compositions and methods for the treatment of neurological disorders CELLIX BIO PRIVATE LIMITED (IN) 2017-08-22 US disclosed
US-9670153-B2 Compositions and methods for the treatment of inflammation and lipid disorders CELLIX BIO PRIVATE LIMITED (IN) 2017-06-06 US disclosed
US-9642915-B2 Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases CELLIX BIO PRIVATE LIMITED (IN) 2017-05-09 US disclosed
US-9624168-B2 Compositions and methods for the treatment inflammation and lipid disorders CELLIX BIO PRIVATE LIMITED (IN) 2017-04-18 US disclosed
US-9604920-B2 Compositions and methods for the treatment of hyperglycemia and metabolic syndrome ALAPATI MOHAN MURALI (IN) 2017-03-28 US disclosed
US-9580383-B2 Compositions and methods for the treatment of multiple sclerosis CELLIX BIO PRIVATE LIMITED (IN) 2017-02-28 US disclosed
US-20150119453-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF DEPRESSION CELLIX BIO PRIVATE LIMITED (IN) 2015-04-30 US disclosed
US-20150119423-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF LOCAL PAIN CELLIX BIO PRIVATE LIMITED (IN) 2015-04-30 US disclosed
US-20150111966-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF FIBROMYALGIA PAIN CELLIX BIO PRIVATE LIMITED (IN) 2015-04-23 US disclosed
US-20150111932-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DEGENERATIVE DISORDERS CELLIX BIO PRIVATE LIMITED (IN) 2015-04-23 US disclosed
US-20150087660-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC DISEASES AND INFLAMMATORY DISORDERS KANDULA MAHESH (IN) 2015-03-26 US disclosed
US-20150087674-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN KANDULA MAHESH (IN) 2015-03-26 US disclosed
US-20150087670-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF RESPIRATORY DISORDERS CELLIX BIO PRIVATE LIMITED (IN) 2015-03-26 US disclosed
US-20150080345-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC SYNDROME CELLIX BIO PRIVATE LIMITED (IN) 2015-03-19 US disclosed
US-20150057347-A1 COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION AND LIPID DISORDERS CELLIX BIO PRIVATE LIMITED (IN) 2015-02-26 US disclosed
US-20120070994-A1 RESIST UNDERLAYER FILM FORMING COMPOSITION CONTAINING SILICON HAVING SULFIDE BOND NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-22 US disclosed